The use of second generation antipsychotics for post-traumatic stress disorder in a US Veterans Health Administration Medical Center

Epidemiology and Psychiatric Sciences

Volumn 23, Issue 3, 2014, Pages 281-288

  Hermes, E ^a   Sernyak, M ^a   Rosenheck, R ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA New England Mental Illness Research   (United States)

Author keywords

Atypical antipsychotics; off label; pharmaco epidemiology; post traumatic stress disorder

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AKATHISIA; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; DROWSINESS; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MOOD DISORDER; OFF LABEL DRUG USE; PATIENT COMPLIANCE; PATIENT PREFERENCE; PHARMACOEPIDEMIOLOGY; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SEDATION; TARDIVE DYSKINESIA; TREATMENT OUTCOME; VETERAN;

EID: 84904797021     PISSN: 20457960     EISSN: 20457979     Source Type: Journal    
DOI: 10.1017/S2045796013000449     Document Type: Article

References (20)

1. pag 281-288 Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 156, 1686-16 96.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association: Washington, DC.
3. Bernardy NC, Lund BC, Alexander B, Friedman MJ (2012). Prescribing trends in veterans with posttraumatic stress disorder. Journal of Clinical Psychiatry 73, 297-303.
4. Greenberg R, Rosenheck R (2007). Department of Veterans Affairs National Mental He alth Program Performance Monitoring System: Fiscal Year 2007 Report. West Haven Connecticut: Northeast Program Evaluation Center, VA Connecticut Healthcare System.
5. Hartung DM, Wisdom JP, Pollack DA, Hamer AM, Haxby DG, Middleton L, McfarlandBH(2008). Patterns of atypical antipsychotic subtherapeutic dosing among oregon medicaid patients. Journal of Clinical Psychiatry 69, 1540-1547.
6. Hermes ED, Rosenheck RA, Desai R, Fontana AF (2012). Recent trends in the treatment of posttraumatic stress disorder and other mental disorders in the VHA. Psychiatric Services 63, 471-476.
7. Hoge CW, Castro CA, Messer SC, McGurk D, C otting DI, Koffman RL (2004). Combat duty in Iraq and Afghanistan. Mental Health Problems, and Barriers to Care. New England Journal of Medicine 351, 13-22.
8. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A, Assunçã o-Talbott S (2009). Akathisia: An updated review focusing on second-generation antipsychotics. Journal of Clinical Psychiatry 70, 627-643.
9. Kok BC, Herrell RK, Thomas JL, Hoge CW (2012). Posttraumatic stress disorder associated with combat service in Iraq or Afghanistan: Reconciling prevalence differences between studies. Journal of Nervous and Mental Disease 200, 444-450.
10. Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, Stock C (2011). Adjunctive risperidone treatment for antidepressant- resistant symptoms of chronic military service-related PTSD. Journal o f American Medical Association 306, 493-502.
11. Leslie DL, Mohamed S, Rosenheck RA (2009). Off-label use of antipsychotic medications in the department of veterans affairs health care system. Psychiatric Services 60, 1175-1181.
12. Lund BC, Bernardy NC, Alexander B, FriedmanMJ (2012). Declining benzodiazepine use in veterans with posttraumatic stress disorder. Journal of Clinical Psychiatry 73, 292-296.
13. Management of Post-Traumatic Stress Working Group (2004). VA/DoD Clinical Practice Guideline for the Management of Post-Traumatic Stress. Department of Veterans Affairs and Department of Defense: Washington, DC.
14. Management of Post-T raumatic StressWorkingGroup (2010a). Management of Post-Traumatic Stress. Department of Veterans Affairs and Department of Defense:Washington, DC.
15. Management of Post-Traumatic Stress Working Group (2010b). Management of Post-Traumatic Stre ss. (Version 2.0). Department of Veterans Affairs and Department of Defense: Washington, DC. Retrieved 1 September 2012 from http://www.healthquality.va.gov/Post-Traumatic-Stress-Disorder-PTSD.asp.
16. Miller DD, Caroff SN, D avis SM, Rosenheck RA, McEvoy JP, Saltz BL, Keefe RSE (2008). Extrapyramidal side-effects of antipsychotics in a randomized trial. British Journal of Psychiatry 193, 279-288.
17. MohamedS, RosenheckRA(2008). Pharmacotherapy ofPTSD in the US Department of Veterans Affairs: Diagnostic-and symptom-guided drug selection. Journal of Clinical Psychiatry 69, 959-965.
18. National Collaborating Centre for Mental Health (2005). Post-traumatic Stress Disorder (PTSD) the Management of PTSD in Adults and Children in Primary and Secondary Care. National Institute for Clinical Excellence (NICE): London.
19. Philip NS, Mello K, Carpenter LL, Tyrka AR, Price LH (2008). Patterns of quetiapine use in psychiatric inpatients: An examination of off-label use. Annals of Clinical Psychiatry 20, 15-20.
20. Robert S, Hamner MB, Kose S, Ulmer HG, Deitsch SE, Lorberbaum JP (2005). Quetiapine improves sleep disturbances in combat veterans with PTSD: Sleep data from a prospective, open-label study. Journal of Clinical Psychopharmacology 25, 387.